Maynard Um
-
-
-
-
-
-
-
Clear Street Reiterates Buy Rating on Protagonist Therapeutics (PTGX)
-
-
-
-
-
-
-
Protagonist Therapeutics (PTGX) Tops Q2 EPS by 16c
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Protagonist Therapeutics (PTGX)
-
-
-
-
-
-
-
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
-
-
-
-
-
-
-
Protagonist Therapeutics (PTGX) PT Raised to $100 at Wedbush
-
-
-
-
-
-
-
Protagonist Therapeutics (PTGX) PT Raised at Truist Ahead of 'Pivotal Year'
-
447,333 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

